This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apple Conference? Forget It. Biotech Is What Really Matters: StockTwits


$ARIA ... this is positive news for "future" growth ? RoyalHouseOfRock (@RoyalHouseOfRock) Jun. 2 at 10:00 AM

MannKind shares rose nearly 3% ahead of the company's presentation at the Jefferies 2014 Global Health Care Conference, scheduled for today at 2:30 p.m. Investors hoped to hear positive news about Afrezza, MannKind's inhaled insulin treatment for diabetics.

$MNKD 4 hours left to the beginning of the conference. ? Donna Peran (@donnaperan) Jun. 2 at 10:20 AM

Afrezza is pending FDA-approval and was overwhelmingly recommended by an FDA subcommittee earlier this year, despite concerns about lung complications with the drug. Investors believe that the drug could take over the $45 billion diabetes-management market, as many diabetics would prefer a treatment that doesn't involve daily shots. Sentiment on the stock is 97% bullish, according to StockTwits analytics.

$MNKD added few more. Like the way she's holding. Expecting a strong action EOD ? Saif Ross (@Rossx) Jun. 2 at 10:24 AM

NPS Pharmaceuticals shares were up nearly 15% by 11 a.m. after a report in the Financial Times that Shire (SHPG) is considering acquiring the company. And investors on said shares should could climb higher than the $35.61 if rumors prove true that Shire secured a $5 billion credit facility to make a bid for the drug company, which focuses on treatments for people with rare disorders.

$NPSP (+21% pre) Shire said to have secured $5B credit facility for a takeover proposal to NPS Pharmaceuticals ? Open Outcrier (@openoutcrier) Jun. 2 at 09:09 AM

$NPSP 5B secured by Shire. Means 5B/106.33M O/S shares = $47.00 buyout price ? PR (@biotechwinner11) Jun. 2 at 07:53 AM

Pharmacyclics rose more than 2% after the company announced that its FDA-approved Imbruvica cancer drug boosted the survival rates of patients with leukemia or small lymphocytic lymphoma better than competing drugs. Patients who received the drug had a 78% reduction in the risk of cancer progression or death.

Sentiment on the stock was overwhelmingly bullish, with 89% of the crowd on StockTwits calling for gains, according to site analytics.

$PCYC This is a good stock to be in if you are not on a 1 - 2 day time horizon. Great data, FDA approved, sales ramping up. ? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:40 AM

Risk is commercialization and potential competitors. That being said, Rx up and great data show Imbruvica can compete vs. Gild/Abbv. ? Christian Balmaceda (@balmacyclics) Jun. 2 at 10:43 AM

>>Read More: Krispy Kreme, Three Others Are Poised for More Volatility

>>Read More: Delta Boosts Order for the Newly Stylish Airbus A321

>>Read More: How to Trade Apple Ahead of Developer Conference, Stock Split

>>Read More: Coal Shares React Positively to EPA Emissions Rules

At the time of publication, the author held no positions in any of the stocks mentioned.

This article represents the opinion of a contributor and not necessarily that of TheStreet or its editorial staff.

2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,356.87 +288.00 1.69%
S&P 500 2,012.89 +40.15 2.04%
NASDAQ 4,644.3120 +96.4780 2.12%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs